The kinase mTOR is an evolutionarily conserved member of the phosphatidylinositol-3-OH kinase (PI(3)K)-related kinase family that has a central role in the regulation of metabolism, protein synthesis, energy balance, proliferation and survival 1 . This kinase senses environmental cues such as amino acids, insulin and growth factors and then integrates such signals to regulate cellular metabolism 2 . It forms the core of two distinct signaling complexes whose activation is regulated differently 3, 4 . The complex mTORC1 contains the scaffolding protein Raptor, as well as the subunits mLST8, PRAS40 and Deptor 5 . Activation of mTORC1 is achieved through signaling by the kinases PI(3)K, PDK1 and Akt. This complex promotes phosphorylation of the translational regulators S6K1 and 4E-BP1 and is believed to have a central role in regulating cellular growth and proliferation by modulating metabolism 6 . The second mTOR signaling complex, mTORC2, consists of mLST8, the scaffolding protein Rictor and the subunits mSIN1 and Protor 5 . Rictor is a critical adaptor protein for mTORC2, and Rictor-deficient mice and mouse embryonic fibroblasts have been shown to lack mTORC2 activity 4 . The activity of mTORC2 can be measured by phosphorylation of the hydrophobic motif of Akt at Ser473 and other kinases of the AGC (protein kinases A, G and C) family (SGK1 and PKC-α) 7 . The exact upstream activators of mTORC2 signaling have yet to be fully elucidated. Despite ongoing studies aimed at delineating both upstream activators and downstream effectors of the two respective signaling pathways, the distinct physiological consequences mediated by mTORC1 and mTORC2 have yet to be defined in biological systems.
A central role for mTOR in sensing the immune microenvironment and dictating immune function and differentiation has begun to emerge 8 . CD4 + T cells that lack mTOR fail to differentiate into effector cells under appropriate skewing conditions 9 . Instead, after activation, mTOR-deficient T cells become Foxp3 + regulatory cells. This inability to differentiate into effector cells in the absence of mTOR is associated with less activation of the transcription factors STAT4, STAT6 and STAT3 in response to the skewing cytokines interleukin 12 (IL-12), IL-4 and IL-6, respectively. Moreover, mTOR controls the development of CD8 + memory T cells in part by regulating expression of the transcription factors T-bet and eomesodermin 10, 11 . In addition, the PI(3)K-mTOR axis regulates lymphocyte trafficking 12 .
The small GTPase Rheb is isolated from the central nervous system and was originally thought to be a mediator of the GTPase Rasmitogen-activated protein kinase pathway 13, 14 . The mammalian Rheb family consists of two proteins, Rheb1 and Rheb2; both are expressed in T cells, but their function has yet to be elucidated 13, 15 . Rheb is a crucial regulator of mTORC1 signaling 16 . The tuberous sclerosis complex (TSC), composed of TSC1 and TSC2, functions as a GTPase-activating protein for Rheb. When TSC is inhibited, the active, GTP-bound form of Rheb interacts with mTORC1 to stimulate its activity 15 .
Despite emerging appreciation for the central role of mTOR in regulating the differentiation of effector T cells, memory T cells and regulatory T cells (T reg cells), the downstream signaling pathways involved in regulating these processes have yet to be elucidated. By selectively
The kinase mTOR has emerged as an important regulator of the differentiation of helper T cells. Here we demonstrate that differentiation into the T H 1 and T H 17 subsets of helper T cells was selectively regulated by signaling from mTOR complex 1 (mTORC1) that was dependent on the small GTPase Rheb. Rheb-deficient T cells failed to generate T H 1 and T H 17 responses in vitro and in vivo and did not induce classical experimental autoimmune encephalomyelitis (EAE). However, they retained their ability to become T H 2 cells. Alternatively, when mTORC2 signaling was deleted from T cells, they failed to generate T H 2 cells in vitro and in vivo but preserved their ability to become T H 1 and T H 17 cells. Our data identify mechanisms by which two distinct signaling pathways downstream of mTOR regulate helper cell fate in different ways. These findings define a previously unknown paradigm that links T cell differentiation with selective metabolic signaling pathways.
A r t i c l e s A r t i c l e s knocking out Rheb in T cells, we demonstrate here that the differentiation of both T helper type 1 (T H 1) and IL-17-producing helper T (T H 17) effector cells required mTORC1 signaling, whereas T H 2 differentiation was preserved. Mice with T cell-specific deletion of Rheb did not mount T H 1 or T H 17 responses in vivo and were resistant to the development of classical experimental autoimmune encephalomyelitis (EAE). As T cells lacking mTORC1 activity were still able to become T H 2 cells, we further investigated the role of mTORC2 signaling in T H 2 development. After deleting mTORC2 signaling in T cells, we found that they were unable to become T H 2 cells but maintained their ability to differentiate into T H 1 cells and T H 17 cells. Our findings define distinct downstream signaling pathways as the mechanisms by which mTOR regulates the differentiation of helper T cells.
RESULTS

Rheb regulates mTORC1 activity in T cells
We hypothesized that genetic deletion of Rheb in T cells would inhibit mTORC1 activation. We bred mice with loxP-flanked Rheb alleles with mice expressing Cre recombinase from the Cd4 promoter and enhancer regions, which led to deletion of Rheb in T cells in the 'T-Rheb −/− ' progeny ( Supplementary Fig. 1 ). We stimulated CD4 + T cells from wild-type and T-Rheb −/− mice with antibody to CD3 (anti-CD3) and anti-CD28 and assessed the activity of mTORC1 and mTORC2 biochemically. After stimulation, wild-type T cells showed considerable phosphorylation of S6K1, indicative of mTORC1 activity ( Fig. 1a,b) . In contrast, S6K1 phosphorylation was almost completely absent in the activated T-Rheb −/− T cells. Phosphorylation of Akt at Thr308 (which is PDK1 dependent and upstream of mTORC1) remained intact in the T-Rheb −/− T cells ( Fig. 1a,b) . Likewise, phosphorylation of Akt at Ser473 (which is downstream of mTORC2) remained intact.
Next we sought to determine the functional consequences of deleting Rheb in T cells. Wild-type and T-Rheb −/− mice had a similar A r t i c l e s frequency of CD8 + T cells, CD4 + T cells and B cells ( Fig. 1c and Supplementary Fig. 2 ). In addition, despite the lack of mTORC1 activity, we did not see any difference between wild-type and T-Rheb −/− mice in the development of Foxp3 + T cells. Similar to T cells lacking mTOR 9 , T cells from the T-Rheb −/− mice did not demonstrate a block in proliferation but instead proliferated more slowly than their wild-type counterparts ( Fig. 1d) . Likewise, IL-2 production was similar in wild-type and T-Rheb −/− T cells ( Fig. 1e ), which indicated that T cell antigen receptor (TCR)-induced activation and subsequent expression of IL-2 was not affected by the absence of Rheb. In some systems, mTOR signaling can affect apoptosis. After in vitro activation, there was no evidence of greater apoptosis in T cells from T-Rheb −/− mice, as assessed by staining with annexin V and 7-aminoactinomycin D (Supplementary Fig. 3 ). Thus, deleting Rheb in T cells specifically eliminates mTORC1 activity while preserving mTORC2 activity. Furthermore, elimination of Rheb in T cells still permits TCR-induced cytokine expression and proliferation.
T H 1 and T H 17 differentiation require mTORC1
Given that mTOR-deficient T cells fail to differentiate into T H 1, T H 2 or T H 17 effector cells, we wanted to determine the effect of Rheb deletion on T cell differentiation. There was no difference between wild-type and T-Rheb −/− littermates in their naive and memory T cell compartments, as assayed with freshly isolated lymphocytes ( Supplementary Fig. 4 ). Similar to T cells lacking mTOR, T-Rheb −/− T cells failed to differentiate into T H 1 cells under the appropriate skewing conditions in vitro ( Fig. 2a) . T-Rheb −/− T cells also failed to differentiate into T H 17 cells ( Fig. 2b) . These observations identify mTORC1 signaling as the downstream mediator of mTOR-dependent T H 1 and T H 17 differentiation. In contrast to mTOR-deficient T cells, T-Rheb −/− T cells were able to differentiate into T H 2 cells ( Fig. 2c) . Therefore, inhibition of mTORC1 activity via deletion of Rheb selectively inhibited T H 1 and T H 17 differentiation but preserved T H 2 differentiation.
To determine if the defect in T H 1 skewing was linked to the proliferative defect in Rheb-deficient T cells, we labeled wild-type and Rheb-deficient T cells with the cytosolic dye CFSE, cultured them in T H 1-or T H 2-skewing conditions and assessed their cytokine production after rechallenge. Rheb-deficient T cells did proliferate in vitro, although at lower rates. Furthermore, Rheb-deficient T cells that divided several times under T H 1-skewing conditions still did not make interferon-γ (IFN-γ) in amounts similar to those of wildtype cells ( Fig. 2d) . Furthermore, the slightly greater IL-4 production observed did not directly correlate with the number of cell divisions. Thus, the inability of Rheb-deficient T cells to differentiate into T H 1 cells was not secondary to their lower rate of proliferation. Next we sought to confirm in vivo the results reported above. Infection with vaccinia virus leads to a robust T H 1 response. We obtained T cells from wild-type and T-Rheb −/− mice crossed onto the OT-II TCR-transgenic background specific for ovalbumin (OVA) and adoptively transferred the cells into wild-type C57BL/6 mice 17 . We infected the recipient mice with vaccinia virus expressing ovalbumin and evaluated clonotypic T cells 5 d later for expression of IFN-γ and IL-4. As expected, wild-type OT-II cells differentiated into T H 1 cells with robust production of IFN-γ, IL-2 and tumor necrosis factor but little IL-4 ( Fig. 3a,b) . In contrast, T-Rheb −/− clonotypic T cells failed to robustly produce IFN-γ but produced substantial IL-4. To assess the role of proliferation in this in vivo system, we labeled OT-II cells with CFSE. Cells transferred into host mice not infected with virus failed to proliferate or produce cytokines after rechallenge, whereas wild-type T cells transferred into immunized mice proliferated in vivo and produced IFN-γ ( Fig. 3c) . However, Rhebdeficient T cells, even those undergoing multiple rounds of proliferation, failed to produce IFN-γ. The addition of an IL-4-neutralizing antibody to the culture conditions failed to restore IFN-γ production (data not shown). These data demonstrate that selective deletion of mTORC1 signaling leads to enhanced T H 2 differentiation. Thus, selective inactivation of mTORC1 in T cells did not lead to T cell tolerance but instead promoted differentiation down an alternative effector pathway.
We also assessed the ability of Rheb-deficient T cells to differentiate into T H 17 cells in vivo. T H 17 cells develop in vivo in the gut in response to pathogens. After brief stimulation with the phorbol ester PMA and ionomycin in vitro, there were considerably fewer in vivo-differentiated CD3 + CD4 + T H 17 cells in the Peyer's patches of T-Rheb −/− mice than in those of wild-type mice (Fig. 3d) . Overall, these data show that T H 1 and T H 17 differentiation are specifically regulated by mTORC1 signaling in vivo and in vitro but T H 2 differentiation is not.
T-Rheb −/− mice are resistant to EAE Because both T H 1 and T H 17 cells are linked to the promotion of autoimmune diseases and IFN-γ and IL-17 participate in promoting the pathology seen in EAE, we determined the susceptibility of the T-Rheb −/− mice to this experimental model 18 . After immunization with myelin oligodendrocyte glycoprotein (MOG) peptide of amino acids 35-55, wildtype mice developed clinical EAE (Fig. 4a) , whereas T-Rheb −/− mice had lower clinical scores, associated with less leukocytic infiltration in the spinal cord and less population expansion of T H 1 and T H 17 cells (Fig. 4b,c) . However, nearly 60% (on average) of MOG-immunized T-Rheb −/− mice developed 'nonclassical EAE' (Supplementary Video 1) , which is characteristic of T H 2 responses to MOG (Fig. 4d) . MOG-specific T H 2 cells or IFN-γ-deficient cells can induce a neurological disorder characterized by ataxia (not paralysis) and infiltration of the cerebellum with cells of the immune response 19 . T-Rheb −/− mice had more leukocytic infiltration, including CD4 + cells in the cerebellum (Fig. 4e) , and T cells isolated from these mice produced more IL-4 and IL-5 in response to MOG peptide in vitro (data not shown). Thus, mTORC1-deficient T cells were neither 'immunodeficient' nor unable to traffick to the CNS. Therefore, selective deletion of mTORC1 signaling leads to enhanced T H 2 differentiation in vivo, even under strongly T H 1-and/or T H 17-promoting conditions.
T H 2 differentiation requires mTORC2 signaling
We further bred mice with loxP-flanked Rictor alleles with mice expressing Cre recombinase from the Cd4 promoter and enhancer Fig. 5 ). After stimulation with anti-CD3 and anti-CD28, T-Rictor −/− T cells had less mTORC2 activity, as determined by phosphorylation of the Akt hydrophobic motif (Ser473). The activity of mTORC1 in these cells was normal, as determined by phosphorylation of S6K1 ( Fig. 5a,b) . In agreement with observations obtained with Rictordeficient mice 7 , proximal (PI(3)K-PDK1) signaling, assessed as phosphorylation of Akt at Thr308, was intact and consistently greater. T-Rictor −/− CD4 + T cells developed normally (with a slightly lower frequency of peripheral CD8 + cells; Supplementary Fig. 6 ) and produced amounts of IL-2 equivalent to those produced by wild-type T cells (Supplementary Fig. 7) , which indicated that TCR-induced signaling was intact. T-Rictor −/− T cells proliferated more slowly after stimulation but had a less severe defect than T-Rheb −/− T cells had (Supplementary Fig. 7 ). In addition, T-Rictor −/− mice did not have more activation-induced apoptosis (Supplementary Fig. 3 ) and had normal proportions of CD4 + T cells in the naive compartment (Supplementary Fig. 8) .
T-Rictor −/− T cells were able to develop into T H 1 and T H 17 cells under the appropriate skewing conditions in vitro (Fig. 5c,d) but failed to differentiate down the T H 2 pathway (Fig. 5e) . To exclude the possibility that the presence of previously activated cells may have altered skewing conditions in our system, we sorted naive (CD62L hi CD44 lo ) CD4 + cells from wild-type, T-Rheb −/− and T-Rictor −/− mice and skewed them with plate-bound anti-CD3 and soluble anti-CD28. As seen with bulk CD4 + T cells, Fig. 9 ). TCR signaling strength can affect T H 1 and T H 2 responses 21 . Specifically, low concentrations of peptide can impair IFN-γ production and create a bias toward the T H 2 response. To assess the effect of strength of peptide signaling on the differentiation of Rheb-deficient and Rictor-deficient T cells, we stimulated wild-type, Rheb-deficient and Rictor-deficient OT-II T cells under conditions of widely varying doses of OVA peptide as described before 22 . However, even at a dose of 100 µM OVA peptide, there was no evidence of more IFN-γ production from Rheb-deficient T cells (Supplementary Fig. 10) . In contrast,
Rheb-deficient cells failed to differentiate into T H 1 or T H 17 cells, and Rictor-deficient cells failed to differentiate into T H 2 cells (Supplementary
Rictor-deficient T cells produced T H 1 cytokines even at exceedingly low doses of peptide.
Consistent with the in vitro data, T-Rictor −/− T cells had robust production of IFN-γ in response to infection with vaccinia virus (Fig. 5f) . Fig. 11 ) associated with numbers of IFN-γ-and IL-17-producing cells in response to MOG peptide equivalent to those in wild-type mice. To assess T H 2 responses in vivo, we primed and boosted wildtype (C57BL/6), T-Rheb −/− and T-Rictor −/− mice with OVA in alum as an adjuvant to elicit a T H 2 response. T-Rictor −/− mice had less induction of IL-4-secreting OVA-specific T cells than did wild-type or T-Rheb −/− mice (Fig. 5g) and failed to generate antigen-specific immunoglobulin G1 antibodies (which are dependent on T H 2 cell help; Fig. 5h ). Thus, mTORC2 regulates the ability of helper T cells to differentiate into T H 2 cells. 
T-Rictor −/− mice had normal susceptibility to EAE (Supplementary
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A r t i c l e s
Distinct STAT activation by mTORC1 and mTORC2
Next we determined if we could reproduce the results reported above in wild-type primary T cells by pharmacological inhibition of mTOR activity. Biochemical analysis of T cells showed that rapamycin inhibited mTORC2 activity 23 (Fig. 6a) . However, very low doses of rapamycin (100-500 pM) selectively inhibit mTORC1 in T cells. Rapamycin at such a very low dose specifically inhibited T H 1 differentiation by naive wild-type T cells activated under either T H 1-or T H 2-skewing conditions (Fig. 6b) , consistent with the findings obtained with Rhebdeficient T cells. It is known that T cells that lack mTOR cannot differentiate into effector cells, in part because they have diminished responses to helper T cell-skewing cytokines 9 . We exposed freshly isolated T cells from wild-type, T-Rheb −/− and T Rictor −/− mice to skewing cytokines and assessed STAT activation. Consistent with their inability to become T H 1 or T H 17 cells, T-Rheb −/− T cells showed less phosphorylation of STAT4 and STAT3 in response to IL-12 and IL-6, respectively (Fig. 6c, left) . However, T-Rheb −/− T cells demonstrated enhanced STAT6 phosphorylation in response to IL-4 (a T H 2-promoting cytokine). T-Rictor −/− T cells showed intact IL-12-and IL-6-induced activation of STAT4 and STAT3, whereas IL-4-induced activation of STAT6 was diminished (Fig. 6c, right) . These findings indicate that the ability of mTORC1 and mTORC2 to regulate the differentiation of effector T cells differently is due in part to their ability to regulate STAT activation differently. In response to different cytokines, Rheb-deficient T cells showed less IL-23-and IFN-β-induced activation of STAT4 and less IL-10-and IL-21-dependent activation of STAT3 (data not shown). Rictor-deficient T cells showed less STAT6 activation in response to IL-13 (data not shown).
Studies have shown that mTOR influences STAT activation 9, 24, 25 . To determine how distinct STAT proteins are regulated differently in T cells, we examined the expression of cytokine receptors on Rheb-and Rictor-deficient T cells. Wild-type, Rheb-deficient and Rictor-deficient T cells all had equivalent expression of the receptors IL-12Rβ1, IL-4R and IL-6R ( Supplementary  Fig. 12) , which indicated that mTOR did not regulate cytokine receptor expression.
STAT activation is partially regulated by the expression of inhibitory SOCS proteins, which can dephosphorylate Jak kinase-dependent residues on STAT proteins in different ways. We assessed the expression patterns of SOCS3 and SOCS5 in the Rheb-and Rictor-deficient T cells. Consistent with published findings [26] [27] [28] , wild-type T cells expressed SOCS3 mRNA and protein at baseline and downregulated its expression after activation (Fig. 6d,e) , whereas SOCS5 expression was low in naive T cells and increased with activation 29, 30 . In resting Rheb-deficient T cells, expression of SOCS3 mRNA and protein was much higher, and these cells retained higher expression after activation (Fig. 6d,e ), whereas SOCS5 expression was similar to that in wild-type cells. Rictordeficient T cells produced SOCS3 at baseline (albeit in smaller amounts than the wild-type cells produced) and this expression decreased after activation, whereas SOCS5 expression was markedly upregulated in the resting cells and remained higher after activation (Fig. 6d,e) . Thus, at baseline and after activation, SOCS3 and SOCS5 are regulated differently in Rheb-deficient and Rictor-deficient T cells.
SOCS protein expression is regulated dynamically over time. To examine the expression patterns of SOCS proteins at later time points, we activated T cells for 48, 72 or 96 h. At these time points, SOCS3 protein remained more abundant in Rheb-deficient T cells, whereas wild-type and Rictor-deficient cells downregulated SOCS3 (Fig. 6f) . Furthermore, whereas wild-type and Rheb-deficient cells consistently upregulated SOCS5 after activation, Rictor-deficient T cells had much more SOCS5 at later time points.
To prove that the larger amounts of SOCS3 in the Rheb-deficient T cells and of SOCS5 in the Rictor-deficient T cells had functional importance, we transfected freshly isolated wild-type, Rheb-deficient and Rictor-deficient CD4 + T cells with small interfering RNA (siRNA) specific for SOCS3 and SOCS5. This resulted in substantial knockdown of SOCS3 and SOCS5 mRNA (Supplementary Fig. 13 ). In T cells stimulated in T H 1 and T H 2 differentiation conditions, knockdown of SOCS3 mRNA resulted in more IFN-γ production in Rheb-deficient T cells (Fig. 6g) , whereas knockdown of SOCS5 mRNA in Rictor-deficient T cells resulted in a greater ability to produce IL-4 ( Fig. 6h) . Such observations demonstrate that SOCS proteins regulate T H 1, T H 17 and T H 2 differentiation in the Rheb-and Rictordeficient T cells. (Fig. 7a,b) . In fact, Rheb-deficient cells had higher expression of GATA-3 than did wild-type cells, consistent with the enhanced ability of Rheb-deficient cells to phosphorylate STAT6 and produce IL-4 in vivo.
In T-Rictor −/− T cells, T-bet and RORγt were transcribed and translated under T H 1 and T H 17 conditions, respectively, but GATA-3 was not expressed under T H 2 conditions (Fig. 7a,b) . In T cells stimulated in T H 1 and T H 2 differentiation conditions, knockdown of SOCS3 mRNA resulted in higher T-bet expression in Rheb-deficient T cells (Fig. 7c) , whereas knockdown of SOCS5 mRNA in Rictor-deficient T cells resulted in higher GATA-3 expression ( Fig. 7c) . Furthermore, wild-type T cells exposed to a very low dose of rapamycin (which inhibits T H 1 development but not T H 2 development) had lower T-bet expression but not lower GATA3 expression in response to the appropriate differentiating conditions (Fig. 7d) . Thus, in the absence of the nutrient-sensitive signaling pathways mediated by mTOR, the ability to respond to cytokines is diminished and T cells fail to properly upregulate lineage-specific transcription factors.
T reg cell development in the absence of mTORC1 and mTORC2
It is known that mTOR-deficient T cells differentiate down a Foxp3 + T reg cell pathway and that inhibition of mTORC1 alone is not sufficient for the generation of T reg cells 9 . Rapamycin can enhance the generation of inducible T reg cells [31] [32] [33] . To determine the specific effect of mTORC1 and mTORC2 on T reg cell differentiation, we cultured wild-type, T-Rheb −/− , T-Rictor −/− and T-Mtor −/− T cells in vitro under activating conditions (in the absence of exogenous transforming growth factor-β (TGF-β)) and then assessed the generation of Foxp3 + T cells. The elimination of neither mTORC1 signaling nor mTORC2 signaling alone led to more Foxp3 + cells (Fig. 8a) . Notably, however, inducible T reg cells (made with TGF-β and IL-2) from wild-type, T-Rheb −/− , T-Rictor −/− mice all seemed to inhibit T cell function equally (Fig. 8b) .
To further test the hypothesis that both mTORC1 and mTORC2 must be inhibited to generate T reg cells, we activated wild-type, T-Rheb −/− and T-Rictor −/− T cells in the presence of a conventional dose of rapamycin (500 nM, which inhibits mTORC1 and mTORC2) or a very low dose of rapamycin (500 pM, which inhibits only mTORC1). Wild-type T cells differentiated into Foxp3 + T cells at the conventional dose of 500 nM (Fig. 8c) . T-Rheb −/− T cells required the mTORC2 inhibition induced by the conventional dose. In contrast, T-Rictor −/− T cells require only the very low dose of rapamycin to differentiate into T reg cells. Finally, the mTOR-specific kinase inhibitor DMK1 (which acutely inhibits both mTOR downstream signaling pathways) 34 promoted the generation of T reg cells from naive wild-type T cells, consistent with our data obtained with mTOR-, mTORC1-and mTORC2-deficient T cells (Fig. 8d) . Thus, inhibition of both mTORC1 and mTORC2 is required for the generation of T reg cells in the absence of exogenous TGF-β.
DISCUSSION
In this report we have defined precise and reciprocal roles for signaling by mTORC1 and mTORC2 in regulating the differentiation of CD4 + helper T cells. Our data have ascribed tissue-distinct physiological functions to mTORC1 and mTORC2. Thus, mTORC1 signaling promotes T H 1 and T H 17 differentiation, mTORC2 A r t i c l e s signaling promotes T H 2 differentiation, and inhibition of mTOR leads to T reg cells. Preliminary studies in our laboratory have failed to demonstrate differences in the activation of mTORC1 and mTORC2 under T H 1-and T H 2-skewing conditions. Therefore, we hypothesize that it is the differences in expression and activation of downstream substrates and signaling pathways that confer on mTORC1 the ability to regulate T H 1 and T H 17 differentiation and confer on mTORC2 the ability to regulate T H 2 differentiation. Our studies provide a critical link between metabolism and T cell differentiation. It is known that mTORC1 signaling integrates growth factors, energy, oxygen and amino acids to promote processes necessary for cell growth 2, 5 . In addition, in T cells, the PI(3)K-Akt-mTORC1 axis is activated by engagement of the coreceptor CD28 and signaling via the IL-2 receptor 35 . IL-7 promotes mTOR activity, helping to prevent atrophy in T cells 36 , whereas IL-4-induced mTOR activity prevents apoptosis 37 . IL-12 and IFN-γ promote the sustained activation of mTORC1 activity in CD8 + T cells 11, 38 . Relatively little is known about the precise role of mTORC2 signaling in regulating cellular function 5 . The ability of mTORC2 to regulate T H 2 differentiation provides potential clues for determining the specific role of mTORC2 in other cell types.
The small GTPase Rheb has been identified as an activator of mTORC1 (ref. 15 ). Our data have demonstrated that Rheb signaling has an important role in regulating T cell differentiation. The same block in differentiation is seen in T cells treated with a very low dose of rapamycin, T cells deficient in mTOR or T cells deficient in Rheb, which supports the hypothesis that the ability of Rheb to direct differentiation is achieved through mTORC1 activation. Furthermore, mTORC1 signaling seems to be both necessary and sufficient for T H 1 and T H 17 differentiation, because Rictor-deficient T cells still maintain their ability to become T H 1 and T H 17 effector cells.
Rictor-deficient T cells generated by crossing of mice expressing Cre from the distal promoter of the gene encoding the kinase Lck (dLck-iCre) and mice with loxP-flanked Rictor alleles have been studied 39 . Consistent with our study, that Rictor deletion inhibited T H 2 differentiation 39 . However, the generation of fewer T H 1 cells (albeit modest compared with T H 2 inhibition) was also reported 39 . The cause of these divergent observations remains unclear. The differences between the two models in their Cre expression might result in subtle differences in T cell development and could affect helper T cell differentiation. Additionally, we found that Rictor-deficient T cells had a greater propensity to differentiate to T H 17 cells than did wildtype cells. In addition, there seem to be differences in signaling in the Rictor-deficient T cells used in each study. Notably, unlike T cells from our mice, which demonstrated robust phosphorylation of Akt Thr308 and subsequent S6K1 activation, T cells in the other study showed less signaling upstream of mTOR 39 , which could also impair mTORC1 signaling. We suggest that when the signaling defects are restricted downstream of mTORC2 signaling, there is a selective block in T H 2 development but not in T H 1 development. Thus, it is possible that the Rictor-deficient T cells in the previously published report 39 act more like mTOR-deficient T cells.
Rapamycin promotes the generation of T reg cells in the absence of exogenous TGF-β [40] [41] [42] . The ligand for the T cell-inhibitory receptor PD-1 has been shown to promote inducible T reg cells by inhibiting mTOR activation 43 . In addition, local depletion of essential amino acids can promote the generation of T reg cells by inhibiting mTOR activity 44 . We have shown here that signaling from both mTORC1 and mTORC2 must be inhibited for skewing of cells down the T reg cell pathway. Our genetic studies were complemented by a pharmacological approach. The simultaneous inhibition of mTORC1 and mTORC2 by an mTOR kinase inhibitor was a potent inducer of T reg cells in the absence of exogenous TGF-β, which indicates that drugs in this class can act as potent agents inducing immunosuppression and tolerance.
Both mTORC1 and mTORC2 can promote cell differentiation in other tissues. Cerebral cortical development is dependent on mTORC1, whereas terminal differentiation of myoblasts is mediated by mTORC2 (refs. 45,46) . In this model, mTORC2 signaling inactivates the Rho-associated kinase ROCK1, which in turn promotes activation of the transcription factors Foxo1 and Foxo3a. We have demonstrated a similar role for signaling by mTORC1 and mTORC2 in regulating distinct tissue-specific transcription factors. It has been shown that rapamycin promotes the differentiation of CD8 + memory cells 10 . Thus, by inhibiting T-bet expression, rapamycin not only inhibits effector functions (such as IFN-γ production) but also promotes the expression of eomesodermin, which in turn promotes the generation of memory T cells 11 . The decrease in helper T cell-specific transcription factors is due to a decrease in specific STAT activation in response to cytokines. Although the IL-12-, IL-6-and IL-4-induced phosphorylation of STAT4, STAT3 and STAT6 was not completely lost in the mTORC1-and mTORC2-deficient T cells, the diminished response contributed to the observed differentiation failure. The ability of mTOR to regulate STAT3 phosphorylation has been described in cancer and neuron activation; however, the precise mechanism for this regulation is unclear 24, 25, 47 . We have demonstrated that in T cells, differences in the expression of SOCS3 and SOCS5 contribute to the STAT-activation defects. Along these lines, mTORC2 inhibits the activity of Foxo transcription factors 7, 48 . Foxo proteins control expression of the transcription factor KLF2, which in turn promotes SOCS5 expression 49 . Preliminary studies have shown that Rictor-deficient T cells have more KLF2, consistent with the observed increase in SOCS5 in these cells (data not shown). We propose a model in which mTORC1 and mTORC2 activate distinct signaling programs, the net sum of which is to promote the differentiation of specific effector cells. Future studies should identify the mTORC1-and mTORC2-specific targets that control differentiation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
